Bellicum Pharmaceuticals, Inc.
BLCM · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $10,199 | $11,409 | $10,175 | $22,197 |
| - Cash | $5,909 | $7,410 | $15,402 | $21,837 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4,290 | $3,999 | -$5,227 | $360 |
| Revenue | $1,000 | $0 | $8 | $500 |
| % Growth | – | -100% | -98.4% | – |
| Gross Profit | $1,000 | $0 | $8 | $500 |
| % Margin | 100% | – | 100% | 100% |
| EBITDA | -$1 | -$7,065 | -$8,645 | -$7,349 |
| % Margin | -0.1% | – | -108,062.5% | -1,469.8% |
| Net Income | -$763 | -$7,352 | -$7,487 | -$6,195 |
| % Margin | -76.3% | – | -93,587.5% | -1,239% |
| EPS Diluted | -0.025 | -0.24 | -0.24 | -0.2 |
| % Growth | 89.7% | 0% | -20% | – |
| Operating Cash Flow | -$1,516 | -$7,993 | -$6,430 | -$6,911 |
| Capital Expenditures | $0 | $1 | -$5 | -$7 |
| Free Cash Flow | -$1,516 | -$7,992 | -$6,435 | -$6,918 |